

Catalog # 10-3141 ABT-263

CAS# 923564-51-6

4-[4-[[2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[4-[[(1R)- 3-(4-morpholinyl)-1-[(phenylthio)methyl]propyl]amino]-3-[(trifluoromethyl)sulfonyl]-phenyl]sulfonyl]-benzamide

Navitoclax

Lot # X109183

Potent and selective Bcl-2 family inhibitor / BH3 domain mimetic which binds to Bcl-2, Bcl-x_L and Bcl-w (K_i<1 nM). A useful tool compound which has shown interesting results in various cancer clinical trials.² Synergizes with deoxyglucose and other agents, inducing apoptosis in cancer cells in a xenograft mouse model.³ A novel senolytic agent, inducing apoptosis preferentially in senescent cells in a cell typerestricted manner.⁴

- 1) Tse et al. (2008), ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor, Cancer Res., 68 3421
- 2) Vogler et al. (2009), Bcl-2 inhibitors: small molecules with a big impact on cancer therapy; Cell Death Differ., **16** 360
- 3) Yamaguchi et al. (2011), Efficient elimination of cancer cells by deoxyglucose-ABT-263/737 combination therapy; PLoS ONE, **6(9)** e24102
- 4) Zhu et al. (2016), Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors; Aging Cell, **15** 428

PHYSICAL DATA

Molecular Weight: 974.61

Molecular Formula: $C_{47}H_{55}CIF_3N_5O_6S_3$ Purity: 98% by HPLC

NMR: (Conforms)

Solubility: DMSO (up to 25 mg/ml)

Physical Description: White solid

Storage and Stability: Store as supplied desiccated at -20°C for up to 2 years from the date of purchase. Solutions in

DMSO may be stored at -20°C for up to 3 months.

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications.